MS3
MCID: MLT094
MIFTS: 27

Multiple Sclerosis 3 (MS3)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Multiple Sclerosis 3

MalaCards integrated aliases for Multiple Sclerosis 3:

Name: Multiple Sclerosis 3 58 76
Multiple Sclerosis, Susceptibility to, 3 58 13
Ms3 58 76

Classifications:



External Ids:

OMIM 58 612595
MeSH 45 D009103
MedGen 43 C2675477

Summaries for Multiple Sclerosis 3

UniProtKB/Swiss-Prot : 76 Multiple sclerosis 3: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.

MalaCards based summary : Multiple Sclerosis 3, also known as multiple sclerosis, susceptibility to, 3, is related to heavy chain disease and depression. An important gene associated with Multiple Sclerosis 3 is MS3 (Multiple Sclerosis, Susceptibility To, 3). The drugs Docetaxel and Antimitotic Agents have been mentioned in the context of this disorder. Affiliated tissues include monocytes, prostate and lung.

Description from OMIM: 612595

Related Diseases for Multiple Sclerosis 3

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Multiple Sclerosis 3 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 heavy chain disease 10.1
2 depression 10.1
3 multiple sclerosis 10.1
4 relapsing-remitting multiple sclerosis 9.7

Symptoms & Phenotypes for Multiple Sclerosis 3

Clinical features from OMIM:

612595

Drugs & Therapeutics for Multiple Sclerosis 3

Drugs for Multiple Sclerosis 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 1 114977-28-5 148124
2 Antimitotic Agents Phase 1
3 Vaccines Phase 1
4 Immunologic Factors Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer Completed NCT00850785 Phase 1
2 The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer Completed NCT01896713 Not Applicable
3 Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples Completed NCT02580799
4 Prostate Screening Study Using MRI in BRCA Carriers Recruiting NCT01990521 Not Applicable

Search NIH Clinical Center for Multiple Sclerosis 3

Genetic Tests for Multiple Sclerosis 3

Anatomical Context for Multiple Sclerosis 3

MalaCards organs/tissues related to Multiple Sclerosis 3:

42
Monocytes, Prostate, Lung, Breast, Brain, Heart, Cortex

Publications for Multiple Sclerosis 3

Articles related to Multiple Sclerosis 3:

(show top 50) (show all 77)
# Title Authors Year
1
Micro-solid phase extraction and LC-MS3 for the determination of triptorelin in rat plasma and application to a pharmacokinetic study. ( 30599277 )
2019
2
Targeted MultiNotch MS3 Approach for Relative Quantification of N-Glycans Using Multiplexed Carbonyl-Reactive Isobaric Tags. ( 29182308 )
2018
3
MS3-IDQ: Utilizing MS3 Spectra beyond Quantification Yields Increased Coverage of the Phosphoproteome in Isobaric Tag Experiments. ( 29461835 )
2018
4
Streamlined Tandem Mass Tag (SL-TMT) Protocol: An Efficient Strategy for Quantitative (Phospho)proteome Profiling Using Tandem Mass Tag-Synchronous Precursor Selection-MS3. ( 29734811 )
2018
5
Mapping phosphate modifications of substituted lipid A via a targeted MS3 CID/UVPD strategy. ( 29881855 )
2018
6
Discrimination of Isoleucine and Leucine by Dimethylation-Assisted MS3. ( 30015478 )
2018
7
Fine mapping and candidate gene identification of the genic male-sterile gene ms3 in cabbage 51S. ( 30238254 )
2018
8
Synthetic cannabinoid isomers characterization by MALDI-MS3 imaging: Application to single scalp hair. ( 30340694 )
2018
9
Fine mapping of the male-sterile genes (MS1, MS2, MS3, and MS4) and development of SNP markers for marker-assisted selection in Japanese cedar (Cryptomeria japonica D. Don). ( 30439978 )
2018
10
Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study. ( 28129749 )
2017
11
A High Resolution/Accurate Mass (HRAM) Data-Dependent MS3 Neutral Loss Screening, Classification, and Relative Quantitation Methodology for Carbonyl Compounds in Saliva. ( 27785693 )
2017
12
The application of multiple analyte adduct formation in the LC-MS3 analysis of valproic acid in human serum. ( 27978470 )
2017
13
Burnout and Depression in MS1 and MS3 Years: A Comparison of Cohorts at One Medical School. ( 28633172 )
2017
14
Imatinib quantification in human serum with LC-MS3 as an effective way of protein kinase inhibitor analysis in biological matrices. ( 28787270 )
2017
15
Advancing a High Throughput Glycotope-centric Glycomics Workflow Based on nanoLC-MS2-product Dependent-MS3 Analysis of Permethylated Glycans. ( 29066631 )
2017
16
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. ( 27461166 )
2016
17
pGlyco: a pipeline for the identification of intact N-glycopeptides by using HCD- and CID-MS/MS and MS3. ( 27139140 )
2016
18
Atypical cleavage of protonated N-fatty acyl amino acids derived from aspartic acid evidenced by sequential MS3 experiments. ( 27565657 )
2016
19
In-Source Decay and Pseudo-MS3 of Peptide and Protein Ions Using Liquid AP-MALDI. ( 27752913 )
2016
20
Highly selective and automated online SPE LC-MS3 method for determination of cortisol and cortisone in human hair as biomarker for stress related diseases. ( 25618673 )
2015
21
γ-Hydroxybutyrate analysis in human serum with liquid chromatography-tandem mass spectrometry on the basis of MS3 mass transition. ( 25703946 )
2015
22
Genomic and phenotypic analyses of Carnobacterium jeotgali strain MS3(T), a lactate-producing candidate biopreservative bacterium isolated from salt-fermented shrimp. ( 25868912 )
2015
23
Syntheses, Characterization, and Optical Properties of Centrosymmetric Ba3(BS3)1.5(MS3)0.5 and Noncentrosymmetric Ba3(BQ3)(SbQ3). ( 25924548 )
2015
24
Dilated Virchow-Robin spaces and multiple sclerosis: 3 T magnetic resonance study. ( 24297592 )
2014
25
Multistage fragmentation of ion trap mass spectrometry system and pseudo-MS3 of triple quadrupole mass spectrometry characterize certain (E)-3-(dimethylamino)-1-arylprop-2-en-1-ones: a comparative study. ( 24701185 )
2014
26
A validated assay to quantitate serotonin in lamb plasma using ultrahigh-performance liquid chromatography-tandem mass spectrometry: applications with LC/MS3. ( 24879539 )
2014
27
MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. ( 24927332 )
2014
28
Sweet-Heart - an integrated suite of enabling computational tools for automated MS2/MS3 sequencing and identification of glycopeptides. ( 23568021 )
2013
29
LC-MS3 quantification of O-glycopeptides in human serum. ( 23765987 )
2013
30
Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. ( 22045554 )
2012
31
Analytical method for the accurate determination of tricothecenes in grains using LC-MS/MS: a comparison between MRM transition and MS3 quantitation. ( 22209956 )
2012
32
The identification of vitamin E homologues in medicinal plant samples using ESI(+)-LC-MS3. ( 22924490 )
2012
33
A pseudo MS3 approach for identification of disulfide-bonded proteins: uncommon product ions and database search. ( 22170466 )
2012
34
MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. ( 21963607 )
2011
35
Influence of a rural family medicine rotation on residency selection: MS3 versus MS4. ( 21918934 )
2011
36
Development of a LC-ESI-MS3 method for determination of nitrendipine in human plasma. ( 21885229 )
2011
37
Comparisons of the postoperative rectus abdominis muscle thickness and the biomechanical properties of donor sites among different subtypes of muscle-sparing transverse rectus abdominis myocutaneous flaps (MS0, MS1, MS2, MS3): a rat model. ( 21301315 )
2011
38
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. ( 20028707 )
2010
39
Molecular detection of targeted major histocompatibility complex I-bound peptides using a probabilistic measure and nanospray MS3 on a hybrid quadrupole-linear ion trap. ( 20932029 )
2010
40
Effect of high-accuracy precursor masses on phosphopeptide identification from MS3 spectra. ( 20426395 )
2010
41
Data-dependent neutral gain MS3: toward automated identification of the N-oxide functional group in drug metabolites. ( 20149682 )
2010
42
Development and validation of a high-throughput method for the quantitative analysis of D-amphetamine in rat blood using liquid chromatography/MS3 on a hybrid triple quadrupole-linear ion trap mass spectrometer and its application to a pharmacokinetic study. ( 19945359 )
2010
43
Detection and identification of 4-hydroxy-2-nonenal Schiff-base adducts along with products of Michael addition using data-dependent neutral loss-driven MS3 acquisition: method evaluation through an in vitro study on cytochrome c oxidase modifications. ( 19771555 )
2009
44
The male sterility locus ms3 is present in a fertility controlling gene cluster in soybean. ( 19617521 )
2009
45
A hierarchical MS2/MS3 database search algorithm for automated analysis of phosphopeptide tandem mass spectra. ( 19288523 )
2009
46
Characterization of 4-hydroxy-2-nonenal-modified peptides by liquid chromatography-tandem mass spectrometry using data-dependent acquisition: neutral loss-driven MS3 versus neutral loss-driven electron capture dissociation. ( 19072288 )
2009
47
The end product of transglutaminase crosslinking: simultaneous quantitation of [Nepsilon-(gamma-glutamyl) lysine] and lysine by HPLC-MS3. ( 18938126 )
2009
48
Investigating MS2/MS3 matching statistics: a model for coupling consecutive stage mass spectrometry data for increased peptide identification confidence. ( 17872894 )
2008
49
Automatic validation of phosphopeptide identifications by the MS2/MS3 target-decoy search strategy. ( 18314942 )
2008
50
PhosphoScan: a probability-based method for phosphorylation site prediction using MS2/MS3 pair information. ( 18549264 )
2008

Variations for Multiple Sclerosis 3

Expression for Multiple Sclerosis 3

Search GEO for disease gene expression data for Multiple Sclerosis 3.

Pathways for Multiple Sclerosis 3

GO Terms for Multiple Sclerosis 3

Sources for Multiple Sclerosis 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....